Correctiv
Support CORRECTIV

We expose injustice. We’re independent and non-profit.

Observational Study “Lemtrada”

Observed Drugs

Title of the Observational Study

PASS: OBS13436: International LEMTRADA Pregnancy Exposure Cohort in Multiple Sclerosis

Registered on
03/23/2015
Start date
03/30/2015
End date
03/31/2012
Executing company
INC Research GmbH
Sponsor
Genzyme Therapeutics, Ltd. (Sanofi)
Number of Docs1
1
Number of Patients2
185
Payment per Patient3
8427.53 €
Fee details
5 Visiten: Enrollment Interview (Ideally < 13 weeks gestation): 2528,26, 2nd Trimester Interview (16-20 weeks gestation): 2528,26, 3rd Trimester Interview (26-32 weeks gestation): 842,75, Pregnancy Outcome Interview (within 6 weeks after the end of pregnancy): 1264,13, Infant status update (1 year after delivery): 1264,13

Background

Independent journalism needs independent funding

Others can write stories. We want to reveal. We are the first investigative newsroom in Germany, which is independent, ad-free, and non-profit.

For us, the core of journalism means uncovering injustice and shortcomings in society. That’s why we investigate corruption in the health system, politicians abusing their power, and an elite that believes that rules are for the others.

To do our job, we need people, who support us. We ask you, too, to become a member and enable the work of 16 investigative journalists at CORRECTIV.

We are convinced that without independent and critical media, democracy fought for and won by our ancestors, cannot survive for long.

Independent Journalism